1824 – Genetic testing for the detection of germline variants in cancer predisposition genes in people with prostate cancer and their relatives

Change to existing Medicare Benefits Schedule items.

Extending eligibility for existing MBS-funded germline testing for variants in BRCA1, BRCA2 and other cancer predisposition genes in patients with breast, ovarian, fallopian tube and primary peritoneal cancer (MBS item 73296) to include those with prostate cancer and their relatives (MBS item 73297).

Type: Investigative 

Prostate cancer is the most commonly diagnosed cancer in Australia with 28,868 new cases estimated in 2025. This cancer develops when genetic differences cause the cells in the prostate gland to grow uncontrollably. These genetic differences may be inherited or acquired, and an estimated 17.2% of patients with prostate cancer carry an inherited pathogenic or likely pathogenic variant in a cancer predisposition gene that may have contributed to the cancer developing.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the application is addressing.   

Before providing your input, please read our Privacy Notice for MSAC consultation input to ensure you are comfortable with how we will use your input.  

The following consultation deadlines apply:

• Pre-PASC consultation deadline: Bypassing PASC
• Pre-MSAC consultation deadline: Friday 12 February 2027 11:59 pm AEDT

For other ways to provide input, see how to have your say.

Find out more about consultation.

This application will be considered at the following meetings:

• PASC meeting: Bypassing PASC
• ESC meeting: 11 to 12 February 2027
• MSAC meeting: 1 to 2 April 2027

Find out more about our meetings.

The outcome of this application is pending.

Find out more about:

• the MSAC process
• application types
• application timelines.